A new initiative aimed at accelerating bowel cancer diagnoses has been launched in Glasgow and its surrounding areas. This pilot program is part of a wider UK effort funded by Cancer Research UK, with additional support from the Bowelbabe Fund. The initiative seeks to enhance the use of Faecal Immunochemical Tests (FIT) for patients exhibiting potential symptoms of bowel cancer.
Scotland experiences one of the highest rates of bowel cancer in the UK, with approximately 4,200 new diagnoses each year. This disease remains the second leading cause of cancer-related deaths in the country, claiming around 1,700 lives annually. The new approach aims to streamline the diagnostic process and improve patient outcomes.
Under the traditional system, further investigation was advised when FIT results indicated at least 10 micrograms of blood per gram of stool. The new initiative raises this threshold for urgent referrals to 20 micrograms, aligning with updated national guidelines. Clinicians have noted that individuals with results between ten and twenty micrograms have a significantly low likelihood of having bowel cancer.
Improving Patient Communication and Monitoring
Dr. Stephen McSorley, the project lead and a consultant colorectal surgeon at NHS Greater Glasgow and Clyde (NHSGGC), emphasized that these changes will facilitate faster diagnoses for those who need it most. He stated, “By refining the FIT threshold and improving communication between primary and secondary care, we aim to ensure the fastest possible diagnosis for those at highest risk, while maintaining safety nets for others.”
For the first time, patients will receive written communications detailing their next steps, which is expected to enhance their understanding and support throughout the diagnostic process. Those with results below the new threshold will still be monitored, with lower-priority referrals made as necessary. Additionally, patients will be offered a second FIT if symptoms persist or if they present with iron deficiency anaemia.
Evaluation of the pilot will be supported by research teams from the Universities of Oxford and Cambridge. Associate Professor Brian Nicholson from the University of Oxford noted that the added safeguards could help prevent missed diagnoses and might guide improvements in diagnostic procedures across the UK.
Addressing National Cancer Treatment Targets
The initiative also aims to assist the health board in meeting the national target of having 95% of patients commence treatment within 62 days of an urgent cancer referral. This goal has not been achieved nationally since 2012. While the pilot focuses solely on symptomatic patients, individuals aged 50 to 74 are still encouraged to participate in Scotland’s national bowel screening program, which operates every two years.
Naser Turabi, Director of Evidence and Implementation at Cancer Research UK, highlighted the importance of addressing diagnostic delays in improving cancer outcomes. He remarked, “Tackling diagnostic delays is critical to improving cancer outcomes, and this project has the potential to make a real difference for patients in the region and beyond.”
This initiative is a significant component of Cancer Research UK’s Test Evidence Transition program, which collaborates with NHS teams to accelerate early diagnosis and enhance standards of care. Through these efforts, Glasgow aims to provide timely and effective care for those at risk of bowel cancer.
